

10/553938

JC12 Rec'd PCT/PTC 21 OCT 2005

"Express Mail" mailing label number EV 393132778 US

Date of Deposit Oct. 21, 2005

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Queen Thomas

Printed Name

Queen Thomas

Signature

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

First Applicant: Jeffry D. Watkins et al.  
For: CD20 Binding  
Docket No.: X-16760A

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provide a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

Paula K. Davis

Paula K. Davis  
Attorney for Applicants  
Registration No. 47,517  
Phone: 317-433-3422

Eli Lilly and Company  
Patent Division, PKD  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

October 19, 2005

FORM PTO 1449 (modified)  INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Atty. Docket No. X-16760A	Serial No
		First Applicant Jeffry D. Watkins et al.	
		Filing Date	Group

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	US 2003/0003097	01-02-2003	Reff et al.	
	AB	US 6,455,043	09-24-2002	Grillo-Lopez	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	BA	WO 03/011878	02-13-2003	Jean-Mairet et al.		
	BB	WO 00/42072	07-20-2000	Presta, L.		
	BC	WO 99/54342	10-28-1999	Jean-Mairet et al.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FORM PTO 1449 (modified)  INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Atty. Docket No. X-16760A	Serial No. <b>10/553938</b>
		First Applicant Jeffry D. Watkins et al.	
		Filing Date	Group

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T <sup>6</sup>
	CA	AME-133, "Superior Potency Compared to Rituxan® in Ex Vivo Model." Retrieved on June 14, 2004 from website <a href="http://www.amevolution.com/Development">http://www.amevolution.com/Development</a> .	
	CB	"AURISTATIN E ADCs, Seattle Genetics," retrieved on June 14, 2004 from website <a href="http://www.iddb.com">http://www.iddb.com</a> .	
	CC	BLAKE, D. et al., "Metal Binding Properties of a Monoclonal Antibody Directed Toward Metal-Chelate Complexes." The Journal of Biological Chemistry, Vol. 271, No. 44, pp. 27677-27685, 1996.	
	CD	BRENSING-KUPPERS, J. et al., "The Human Immunoglobulin k Locus on Yeast Artificial Chromosomes (YACs)." Gene, Vol. 191, pp. 173-181, 1997.	
	CE	"(BW) (CA-GENENTECH/IDEC) (DNA) (IDPH) Genentech and IDEC Announce Humanized Anti-CD20 Antibody Development Collaboration," retrieved on June 14, 2004 from website <a href="http://www.businesswire.com">http://www.businesswire.com</a> .	
	CF	CHESON, B., "Bexxar Corixa/GlaxoSmithKline." Current Opinion in Investigational Drugs, Vol. 3, No. 1, pp. 165-170, 2002.	
	CG	CHIU, YA-WEN et al., "Selective Binding of Polychlorinated Biphenyl Congeners by a Monoclonal Antibody: Analysis by Kinetic Exclusion Fluorescence Immunoassay." Anal. Chem, Vol. 73, pp. 5477-5484, 2001.	
	CH	DALL' ACQUA et al., "Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences." The Journal of Immunology, Vol. 169, pp. 5171-5180, 2002.	
	CI	EDWARDS, J. and Cambridge, G., "Sustained Improvement in Rheumatoid Arthritis Following a Protocol Designed to Deplete B Lymphocytes." Rheumatology, Vol. 40, No. 2, pp. 205-211, 2001.	
	CJ	"GENMAB Announces Humax-CD20 Program," retrieved on June 14, 2004 from website <a href="http://www.genmab.com">http://www.genmab.com</a> .	
	CK	"GENMAB: Selected Genmab Literature," retrieved on June 14, 2004 from website <a href="http://www.genmab.com">http://www.genmab.com</a> .	
	CL	"GENENTECH and IDEC Announce Humanized Anti-CD20 Antibody Development Collaboration," retrieved on June 23, 2003 from website <a href="http://biz.yahoo.com">http://biz.yahoo.com</a> .	
	CM	GHETIE, V. et al., "Increasing the Serum Persistence of an IgG Fragment by Random Mutagenesis." Nature Biotechnology, Vol. 15, pp. 637-640, 1997.	

Examiner Signature	Date Considered	
--------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	CN	HONGO, J. et al., "Characterization of Novel Neutralizing Monoclonal Antibodies Specific to Human Neurturin." <i>Hybridoma</i> , Vol. 19, No. 4, pp. 303-315, 2000.	
	CO	"HUMAX-CD20," retrieved on June 14, 2004 from website <a href="http://www.iddb.com">http://www.iddb.com</a> .	
	CP	KAWASAKI, K. et al., "Evolutionary Dynamics of the Human Immunoglobulin $k$ Locus and the Germline Repertoire of the $V_k$ Genes." <i>Eur. J. Immunol.</i> , Vol. 31, pp. 1017-1028, 2001.	
	CQ	KAWASAKI, K. et al., "One-Megabase Sequence Analysis of the Human Immunoglobulin $\lambda$ Gene Locus." <i>Genome Research</i> , Vol. 7, pp. 250-261, 1997.	
	CR	KHOSRAVIANI, M. et al., "Binding Properties of a Monoclonal Antibody Directed Toward Lead-Chelate Complexes." <i>Bioconjugate Chem.</i> Vol. 11, pp. 267-277, 2000.	
	CS	KIM, Jin-Kyoo et al., "Mapping the Site on Human IgG for Binding of the MHC Class 1-Related Receptor, FcRn." <i>Eur. J. Immunol.</i> , Vol. 29, pp. 2819-2825, 1999.	
	CT	"IBRUTUMOMAB TIUXETAN," retrieved on June 14, 2004 from website <a href="http://www.iddb.com">http://www.iddb.com</a>	
	CU	ILLIDGE, T. and BAYNE, M., "Antibody Therapy of Lymphoma." <i>Expert Opin. Pharmacother.</i> , Vol. 2, No. 6, pp. 953-961, 2001.	
	CV	MEDESAN, C. et al., "Comparative Studies of Rat IgG to Further Delineate the Fc: FcRn Interaction Site." <i>Eur. J. Immunol.</i> , Vol. 28, pp. 2092-2100, 1998.	
	CW	POWERS, D. et al., "Expression of Single-Chain Fv-Fc Fusions in <i>Pichia Pastoris</i> ." <i>Journal of Immunological Methods</i> , Vol. 251, pp. 123-135, 2001.	
	CX	"R-1594," retrieved on June 14, 2004 from website <a href="http://www.iddb.com">http://www.iddb.com</a> .	
	CY	"RITUXIMAB," retrieved on June 14, 2004 from website <a href="http://www.iddb.com">http://www.iddb.com</a> .	
	CZ	SCHABLE and ZACHAU, "The Variable Genes of the Human Immunoglobulin $\chi$ Locus." <i>Biol. Chem. Hoppe-Seyler</i> , Vol. 374, pp. 1001-1022, 1993.	
	CAA	SELDIN, D., "Techniques for Using Bexxar for the Treatment of Non-Hodgkin's Lymphoma." <i>Journal of Nuclear Medicine Technology</i> , Vol. 30, No. 3, pp. 109-114, 2002.	
	CAB	SHIELDS, R. et al., "High Resolution Mapping of the Binding Site on Human IgG1 for Fc $\gamma$ RI, Fc $\gamma$ RII, Fc $\gamma$ RIII, and FcRn and Design of IgG1 Variants with Improved Binding to the Fc $\gamma$ R." <i>The Journal of Biological Chemistry</i> , Vol. 276, No. 9, pp. 6591-6604, 2001.	
	CAC	STEIN, R. et al., "Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin's Lymphoma." <i>Clinical Cancer Research</i> , Vol. 10, pp. 2868-2878, 2004.	
	CAD	"TOSITUMOMAB," retrieved on June 14, 2004 from website <a href="http://www.iddb.com">http://www.iddb.com</a> .	

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	CAE	UMANA, P. et al., "Engineered Glycoforms of an Antineuro-blastoma IgG1 with Optimized Antibody-dependent Cellular Cytotoxic Activity." <i>Nature Biotechnology</i> , Vol. 17, pp. 176-180, 1999.	
	CAF	VASSEROT, A. et al., "Optimization of Protein Therapeutics by Directed Evolution." <i>Drug Discovery Today</i> , Vol. 8, No. 3, pp. 118-126, 2003.	
	CAG	WU, H., "Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues." <i>J. Mol. Biol.</i> , Vol. 294, pp. 151-162, 1999.	

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.